LY3884961
Sponsors
Prevail Therapeutics Inc., Prevail Therapeutics
Conditions
Gaucher DiseaseGaucher Disease, Type 1Gaucher Disease, Type 2Parkinson DiseaseParkinson’s Disease with at Least One GBA1 MutationType 1 Gaucher Disease (Peripheral/Non-neuronopathic Manifestations)
Phase 1
Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)
Active, not recruitingNCT04127578
Start: 2020-01-03End: 2030-12-31Target: 32Updated: 2026-03-13
Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)
Active, not recruitingNCT04411654
Start: 2021-06-29End: 2028-05-01Updated: 2026-04-01
A Clinical Trial of PR001 (LY3884961) in Patients With Peripheral Manifestations of Gaucher Disease (PROCEED)
RecruitingNCT05487599
Start: 2022-12-20End: 2031-11-30Target: 15Updated: 2025-12-08
An Open-label, Dose-Finding, Phase 1/2 Study to Evaluate the Safety and Tolerability of a Single Intravenous Dose of LY3884961 in Subjects with Peripheral Manifestations of Gaucher Disease
SuspendedCTIS2022-500281-10-02
Start: 2023-10-18Target: 6Updated: 2025-09-11
A Phase 1/2a Open-Label Ascending Dose Study to Evaluate the Safety and Effects of LY3884961 in Patients with Parkinson’s Disease with at Least One GBA1 Mutation (PROPEL)
WithdrawnCTIS2024-519587-40-00
Target: 5Updated: 2025-06-16